PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
6.22%
Cash & equivalents growing 6.22% while CRVO's declined -12.90%. Peter Lynch would see this as a sign of superior liquidity management.
-100.00%
Both CRVO and the company show zero Short-Term Investments Growth.
6.22%
Below half of CRVO's -12.90%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of CRVO's 100.00%. David Dodd sees a leaner approach to short-term items.
13.80%
Below half of CRVO's -10.68%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
2.11%
Below half CRVO's 624.23%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.11%
Below half of CRVO's 54.89%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
13.78%
Below half of CRVO's 44.18%. Michael Burry sees a potential red flag for stagnation or capital shortage.
62.36%
Above 1.5x CRVO's 5.36%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-40.14%
Less than half of CRVO's 57.04%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
133.46%
Higher Deferred Revenue (Current) Growth compared to CRVO's zero value, indicating better performance.
184.58%
Exceeding 1.5x CRVO's 41.58%. Michael Burry suspects ballooning short-term obligations vs. competitor.
173.41%
Above 1.5x CRVO's 20.46%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
173.41%
Above 1.5x CRVO's 19.82%. Michael Burry sees a potential leverage warning sign.
4.06%
Less than half of CRVO's 49.36%. David Dodd sees fewer share issuances vs. competitor.
-25.11%
≥ 1.5x CRVO's -2.51%. David Dodd sees higher yoy retained profits than competitor.
-90.06%
Higher AOCI Growth compared to CRVO's zero value, indicating worse performance.
-100.00%
Higher Other Stockholders' Equity Items Growth compared to CRVO's zero value, indicating worse performance.
-763.59%
Below half CRVO's 89.12%. Michael Burry sees potential underperformance in building shareholder capital.
13.78%
Below half CRVO's 44.18%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Both CRVO and the company show zero Total Investments Growth.
-40.14%
Less than half of CRVO's 57.04%. David Dodd sees less overall debt expansion vs. competitor.
-7.59%
Less than half of CRVO's 68.11%. David Dodd sees better deleveraging or stronger cash buildup than competitor.